Table 2 Univariate and multivariate analysis for progression-free survival.

Age (years)

≥69/ < 69

1.08

0.68–1.71

0.75

Sex

Male/female

0.77

0.44–1.33

0.35

ECOG-PS

1–2/0

2.03

1.20–3.45

0.0087

2.17

1.25–3.75

0.0057

Histology

Differentiated/undifferentiated

1.21

0.74–1.97

0.45

HER2 status

Positive/negative

1.50

0.85–2.65

0.16

Liver metastasis

Positive/negative

0.86

0.54–1.38

0.52

Number of metastatic organs

≥2/ ≤ 1

0.94

0.58–1.52

0.81

Previous gastrectomy

Presence/absence

0.70

0.44–1.12

0.14

LDH (U/L)

≥214/ < 214

1.32

0.82–2.13

0.26

Haemoglobin (g/dL)

≥10.6/ < 10.6

0.99

0.62–1.57

0.96

NLR

≥2.37/ < 2.37

1.69

1.06–2.70

0.027

1.80

1.11–2.92

0.017

Albumin (g/dL)

≥3.5/ < 3.5

0.72

0.45–1.14

0.16

CRP (mg/dL)

≥1.0/ < 1.0

1.48

0.83–2.62

0.18

CRP kinetics

Spike/others

0.31

0.13–0.73

0.0074

0.38

0.16–0.91

0.029

Age (years)

≥70/ < 70

1.09

0.65–1.83

0.74

Sex

Male/female

1.27

0.65–2.47

0.49

ECOG-PS

1–2/0

1.37

0.74–2.53

0.32

Liver metastasis

Positive/negative

1.03

0.54–1.93

0.94

Number of metastatic organs

≥2/ ≤ 1

0.93

0.56–1.55

0.79

Previous surgery

Presence/absence

1.28

0.72–2.26

0.40

Previous radiation therapy

Presence/absence

0.88

0.52–1.49

0.63

LDH (U/L)

≥175/ < 175

0.87

0.50–1.51

0.62

Haemoglobin (g/dL)

≥11.2/ < 11.2

0.77

0.46–1.27

0.30

NLR

≥3.65/ < 3.65

1.16

0.70–1.94

0.56

Albumin (g/dL)

≥3.8/ < 3.8

0.52

0.31–0.88

0.014

0.78

0.44–1.39

0.39

CRP (mg/dL)

≥1.0/ < 1.0

2.29

1.33–3.96

0.0029

1.83

0.99–3.38

0.054

CRP kinetics

Spike/others

0.22

0.095–0.53

0.0006

0.28

0.12–0.68

0.0044